The Efficacy and Toxicity of Neoadjuvant Chemotherapy Regimens of Epirubicin Plus Cyclophosphamide Followed by Docetaxel or Paclitaxel in Female Breast Cancer Patients

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi:10.3322/caac.2144229313949
   PubMed Web of Science ®Google Scholar
• Mieog JS, van der Hage JA, van de Velde CJ. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev. 2007;CD005002.17443564
   PubMed Web of Science ®Google Scholar
• Peto R, Davies C, Godwin J, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. Lancet. 2012;379(9814):432–444. doi:10.1016/S0140-6736(11)61625-522152853
   PubMed Web of Science ®Google Scholar
• Vriens BE, Aarts MJ, de Vries B, et al., Breast Cancer Trialists’ Group of the Netherlands (BOOG). Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer. Eur J Cancer. 2013;49(15):3102–3110. doi:10.1016/j.ejca.2013.06.01223850450
   PubMed Web of Science ®Google Scholar
• Wu J, Li S, Jia W, Su F. Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer. J Cancer Res Clin Oncol. 2011;137(10):1505–1510. doi:10.1007/s00432-011-1029-621830158
   PubMed Web of Science ®Google Scholar
• Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11(16):5678–5685. doi:10.1158/1078-0432.CCR-04-242116115903
   PubMed Web of Science ®Google Scholar
• Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329–2334. doi:10.1158/1078-0432.CCR-06-110917438091
   PubMed Web of Science ®Google Scholar
• Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275–1281. doi:10.1200/JCO.2007.14.414718250347
   PubMed Web of Science ®Google Scholar
• Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007;109(9):1721–1728. doi:10.1002/cncr.2261817387718
   PubMed Web of Science ®Google Scholar
• Smid M, Wang Y, Zhang Y, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008;68(9):3108–3114. doi:10.1158/0008-5472.CAN-07-564418451135
   PubMed Web of Science ®Google Scholar
• Wolmark. N, Wang. J, Mamounas. E, Bryant. J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from national surgical adjuvant breast and bowel project B-18. J Natl Cancer Inst Monogr. 2001;2001(30):96–102. doi:10.1093/oxfordjournals.jncimonographs.a003469
   Google Scholar
• Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol. 2003;21(22):4165–4174. doi:10.1200/JCO.2003.12.00514559892
   PubMed Web of Science ®Google Scholar
• Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol. 2008;26(5):778–785. doi:10.1200/JCO.2007.15.023518258986
   PubMed Web of Science ®Google Scholar
• Guarneri V, Broglio K, Kau SW, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol. 2006;24(7):1037–1044. doi:10.1200/JCO.2005.02.691416505422
   PubMed Web of Science ®Google Scholar
• Burcombe RJ, Makris A, Richman PI, et al. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer. 2005;92(1):147–155. doi:10.1038/sj.bjc.660225615611798
   PubMed Web of Science ®Google Scholar
• Schott. AF, Hayes DF. Defining the benefits of neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2012;30(15):1747–1749. doi:10.1200/JCO.2011.41.316122508810
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuIRE WL. Human breast cancer: correlation of relapse and survival with amplification of theHER-2lneu oncogene. Science. 1987;235(4785):177–182. doi:10.1126/science.37981063798106
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin W, Jones LA. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707–712. doi:10.1126/science.24701522470152
   PubMed Web of Science ®Google Scholar
• Kathleen MD, Pritchard I, Shepherd LE, O’Malley FP, Andrulis IL. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med. 2006;354(20):2103–2111. doi:10.1056/NEJMoa05450416707747
   PubMed Web of Science ®Google Scholar
• Gianni L, Zambetti M, Clark K, et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol. 2005;23(29):7265–7277. doi:10.1200/JCO.2005.02.081816145055
   PubMed Web of Science ®Google Scholar
• Schrama JG, Faneyte IF, Schornagel JH, et al. Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up. Ann Oncol. 2002;13(5):689–698. doi:10.1093/annonc/mdf20312075736
   PubMed Web of Science ®Google Scholar
• Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/cancer and leukemia group B trial 9741. J Clin Oncol. 2003;21(8):1431–1439. doi:10.1200/JCO.2003.09.08112668651
   PubMed Web of Science ®Google Scholar
• BONADONNA MDGIANNI, PINUCCIA VALAGUSSA BS, Moliterni Mdangela. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med. 1995;332(14):901–906. doi:10.1056/NEJM1995040633214017877646
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796–1804. doi:10.1200/JCO.2011.38.859522508812
   PubMed Web of Science ®Google Scholar
• Loo WT, Yip MC, Chow LW, et al. A pilot study: application of hemoglobin and cortisol levels, and a memory test to evaluate the quality of life of breast cancer patients on chemotherapy. Int J Biol Markers. 2013;28(4):e348–356. doi:10.5301/JBM.500005324338719
   PubMed Web of Science ®Google Scholar
• Denison. U, Baumann J, Peters-Engl C, Samonigg H. Incidence of anaemia in breast cancer patients receiving adjuvant chemotherapy. Breast Cancer Res Treat. 2003;79(3):347–353. doi:10.1023/A:102401650892512846419
   PubMed Web of Science ®Google Scholar
• Paz M, Gomes ALJ, Islam MT, et al. Assessment of chemotherapy on various biochemical markers in breast cancer patients. J Cell Biochem. 2018;119(3):2923–2928. doi:10.1002/jcb.2648729120088
   PubMed Web of Science ®Google Scholar
• Luca Gianni WE, Semiglazov V, Lluch A, et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol. 2014;15.
   Web of Science ®Google Scholar